Accelerating Discovery of Functional Mutant Alleles in Cancer

Published on Dec 15, 2017in Cancer Discovery26.37
· DOI :10.1158/2159-8290.CD-17-0321
Matthew T. Chang19
Estimated H-index: 19
(UCSF: University of California, San Francisco),
Tripti Shrestha Bhattarai1
Estimated H-index: 1
(MSK: Memorial Sloan Kettering Cancer Center)
+ 31 AuthorsBarry S. Taylor71
Estimated H-index: 71
(MSK: Memorial Sloan Kettering Cancer Center)
Most mutations in cancer are rare, which complicates the identification of therapeutically significant mutations and thus limits the clinical impact of genomic profiling in cancer patients. Here, we analyzed 24,592 cancers including 10,336 prospectively sequenced patients with advanced disease to identify mutant residues arising more frequently than expected in the absence of selection. We identified 1,165 statistically significant hotspot mutations of which 80% arose in 1 in 1000 or fewer patients. Of 55 recurrent in-frame indels, we validated that novel AKT1 duplications induced pathway hyperactivation and conferred AKT inhibitor sensitivity. Cancer genes exhibit different rates of hotspot discovery with increasing sample size, with few approaching saturation. Consequently, 26% of all hotspots in therapeutically actionable oncogenes were novel. Upon matching a subset of affected patients directly to molecularly targeted therapy, we observed radiographic and clinical responses. Population-scale mutant allele discovery illustrates how the identification of driver mutations in cancer is far from complete.
  • References (30)
  • Citations (52)
📖 Papers frequently viewed together
244 Citations
204 Citations
3,544 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Ryan J. Sullivan (Harvard University)H-Index: 46
#2Jeffrey R. Infante (Sarah Cannon Research Institute)H-Index: 49
Last. Bob T. Li (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 20
view all 27 authors...
Ulixertinib (BVD-523) is an ERK1/2 kinase inhibitor with potent preclinical activity in BRAF- and RAS-mutant cell lines. In this multicenter phase I trial (NCT01781429), 135 patients were enrolled to an accelerated 3 + 3 dose-escalation cohort and six distinct dose-expansion cohorts. Dose escalation included 27 patients, dosed from 10 to 900 mg twice daily and established the recommended phase II dose (RP2D) of 600 mg twice daily. Ulixertinib exposure was dose proportional to the RP2D, which pro...
54 CitationsSource
#1Debyani Chakravarty (Philips)H-Index: 26
#2Jianjiong Gao (Philips)H-Index: 1
Last. Nikolaus Schultz (Philips)H-Index: 3
view all 48 authors...
204 CitationsSource
#1Ahmet ZehirH-Index: 34
#2Ryma BenayedH-Index: 22
Last. Michael F. BergerH-Index: 80
view all 100 authors...
498 CitationsSource
#1Tracy L. Stockley (U of T: University of Toronto)H-Index: 20
#2Amit M. Oza (U of T: University of Toronto)H-Index: 54
Last. Philippe L. Bedard (U of T: University of Toronto)H-Index: 37
view all 30 authors...
Background The clinical utility of molecular profiling of tumor tissue to guide treatment of patients with advanced solid tumors is unknown. Our objectives were to evaluate the frequency of genomic alterations, clinical “actionability” of somatic variants, enrollment in mutation-targeted or other clinical trials, and outcome of molecular profiling for advanced solid tumor patients at the Princess Margaret Cancer Centre (PM).
69 CitationsSource
The Genomic Data Commons will initially house raw genomic data and diagnostic, histologic, and clinical outcome data from National Cancer Institute–funded projects. A harmonization process will align sequencing data to the genome and identify mutations and alterations.
288 CitationsSource
#1Monkol Lek (Broad Institute)H-Index: 37
#2Konrad J. Karczewski (Broad Institute)H-Index: 37
Last. Daniel G. MacArthur (Broad Institute)H-Index: 58
view all 79 authors...
Large-scale reference data sets of human genetic variation are critical for the medical and functional interpretation of DNA sequence changes. Here we describe the aggregation and analysis of high-quality exome (protein-coding region) DNA sequence data for 60,706 individuals of diverse ancestries generated as part of the Exome Aggregation Consortium (ExAC). This catalogue of human genetic diversity contains an average of one variant every eight bases of the exome, and provides direct evidence fo...
4,484 CitationsSource
#1Alice H. Berger (Broad Institute)H-Index: 15
#2Angela N. Brooks (Broad Institute)H-Index: 24
Last. Jesse S. Boehm (Broad Institute)H-Index: 38
view all 31 authors...
Recent genome sequencing efforts have identified millions of somatic mutations in cancer. However, the functional impact of most variants is poorly understood. Here we characterize 194 somatic mutations identified in primary lung adenocarcinomas. We present an expression-based variant-impact phenotyping (eVIP) method that uses gene expression changes to distinguish impactful from neutral somatic mutations. eVIP identified 69% of mutations analyzed as impactful and 31% as functionally neutral. A ...
69 CitationsSource
#1Eejung Kim (Broad Institute)H-Index: 9
#2Nina Ilic (Broad Institute)H-Index: 9
Last. William C. Hahn (Broad Institute)H-Index: 111
view all 28 authors...
Cancer genome characterization efforts now provide an initial view of the somatic alterations in primary tumors. However, most point mutations occur at low frequency, and the function of these alleles remains undefined. We have developed a scalable systematic approach to interrogate the function of cancer-associated gene variants. We subjected 474 mutant alleles curated from 5,338 tumors to pooled in vivo tumor formation assays and gene expression profiling. We identified 12 transforming alleles...
44 CitationsSource
#1Amanda R. MooreH-Index: 4
#2Emilie CeraudoH-Index: 4
Last. Yu ChenH-Index: 34
view all 14 authors...
Yu Chen and colleagues describe a new constitutively activating mutation in the G-protein-coupled receptor CYSLTR2 in patients with uveal melanoma lacking mutations in the G-protein-encoding genes GNAQ and GNA11. They find that expression of the mutant leads to increased expression of melanocyte-lineage signature genes and promotes tumorigenesis in vivo.
72 CitationsSource
#1Scott A. Foster (Genentech)H-Index: 3
#2Daniel M. Whalen (Genentech)H-Index: 2
Last. Shiva Malek (Genentech)H-Index: 18
view all 21 authors...
Summary Activating mutations in protein kinases drive many cancers. While how recurring point mutations affect kinase activity has been described, the effect of in-frame deletions is not well understood. We show that oncogenic deletions within the β3-αC loop of HER2 and BRAF are analogous to the recurrent EGFR exon 19 deletions. We identify pancreatic carcinomas with BRAF deletions mutually exclusive with KRAS mutations. Crystal structures of BRAF deletions reveal the truncated loop restrains αC...
63 CitationsSource
Cited By52
#1Sharadha Sakthikumar (Broad Institute)H-Index: 12
#1Sharadha Sakthikumar (Science for Life Laboratory)
Last. Karin Forsberg-Nilsson (Science for Life Laboratory)H-Index: 22
view all 8 authors...
Whole Genome Sequencing of Glioblastoma Reveals Enrichment of Non-Coding Constraint Mutations in Known and Novel Genes
1 CitationsSource
#1Nicholas J. Olson (Dartmouth–Hitchcock Medical Center)H-Index: 3
#2Rodrigo Gularte-Mérida (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 5
Last. Konstantinos Linos (Dartmouth–Hitchcock Medical Center)H-Index: 5
view all 8 authors...
Aims. The aim of this study was to identify potential driver genetic alterations in a dedifferentiated liposarcoma (DDLPS) with rhabdomyosarcomatous differentiation. Methods and Results. A 24-year-...
#1Alexander N. Gorelick (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 5
#2Francisco J. Sánchez-Rivera (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 12
Last. Noah D. Friedman (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 1
view all 18 authors...
Cancers develop as a result of driver mutations1,2 that lead to clonal outgrowth and the evolution of disease3,4. The discovery and functional characterization of individual driver mutations are central aims of cancer research, and have elucidated myriad phenotypes5 and therapeutic vulnerabilities6. However, the serial genetic evolution of mutant cancer genes7,8 and the allelic context in which they arise is poorly understood in both common and rare cancer genes and tumour types. Here we find th...
#1Antonio Rodriguez (University of Bern)
#2John Gallon (University of Basel)
Last. Scott A. Tomlins (UM: University of Michigan)H-Index: 69
view all 24 authors...
Lethal prostate cancer commonly metastasizes to bone, lymph nodes, and visceral organs but with more effective therapies, there is an increased frequency of metastases to the brain. Little is known about the genomic drivers of prostate cancer brain metastases (PCBM). To address this, we conducted a comprehensive multi–regional, genomic, and targeted transcriptomic analysis of PCBM from 28 patients. We compared whole–exome and targeted RNA sequencing with matched primary tumors when available (n ...
#1Marina Stasenko (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 2
#2Noah Z. Feit (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 1
Last. Mario M. Leitao (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 40
view all 15 authors...
OBJECTIVE: Despite good prognosis for patients with low-risk endometrial cancer, a small subset of women with low-grade/low-stage endometrial cancer experience disease recurrence and death. The aim of this study was to characterize clinical features and mutational profiles of recurrent, low-grade, non-myoinvasive, 'ultra-low risk' endometrioid endometrial adenocarcinomas. METHODS: We retrospectively identified patients with International Federation of Gynecology and Obstetrics (FIGO) stage IA en...
1 CitationsSource
#1Chey Loveday (ICR: Institute of Cancer Research)H-Index: 12
#2Kevin Litchfield (UCL: University College London)H-Index: 19
Last. Darshna Dudakia (ICR: Institute of Cancer Research)H-Index: 14
view all 25 authors...
While most testicular germ cell tumours (TGCTs) exhibit exquisite sensitivity to platinum chemotherapy, ~10% are platinum resistant. To gain insight into the underlying mechanisms, we undertake whole exome sequencing and copy number analysis in 40 tumours from 26 cases with platinum-resistant TGCT, and combine this with published genomic data on an additional 624 TGCTs. We integrate analyses for driver mutations, mutational burden, global, arm-level and focal copy number (CN) events, and SNV and...
1 CitationsSource
#1Fresia Pareja (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 13
#2Michael S. Toss (NUH: Nottingham University Hospitals NHS Trust)H-Index: 1
Last. Emad A. Rakha (NUH: Nottingham University Hospitals NHS Trust)H-Index: 54
view all 21 authors...
AIMS: Breast adenomyoepitheliomas (AMEs) are uncommon tumors. Most estrogen receptor (ER)-positive AMEs have mutations in PI3K pathway genes, whereas ER-negative AMEs usually harbor concurrent mutations affecting the HRAS Q61 hotspot and PI3K pathway genes. Here, we sought to determine the sensitivity and specificity of RAS Q61R immunohistochemical (IHC) analysis for detection of HRAS Q61R mutations in AMEs. METHODS AND RESULTS: 26 AME (14 ER-positive, 12 ER-negative) previously subjected to mas...
1 CitationsSource
#1C. Fortuno (NIH: National Institutes of Health)
#2Kristy Lee (UNC: University of North Carolina at Chapel Hill)H-Index: 12
Last. Bing Jian Feng (UofU: University of Utah)H-Index: 27
view all 23 authors...
Germline pathogenic variants in TP53 are associated with Li-Fraumeni syndrome (LFS), an autosomal dominant cancer predisposition disorder associated with high risk of malignancy, including early onset breast cancers, sarcomas, adrenocortical carcinomas and brain tumors. Intense cancer surveillance for individuals with TP53 germline pathogenic variants has been shown to decrease mortality; therefore, accurate and consistent classification of variants across clinical and research laboratories is c...
#1Yonina R. Murciano-Goroff (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 1
#2Barry S. TaylorH-Index: 71
Last. Alison M. Schram (Cornell University)H-Index: 4
view all 4 authors...
Prospective molecular characterization of cancer has enabled physicians to define the genomic changes of each patient's tumor in real time and select personalized therapies based on these detailed portraits. Despite the promise of such an approach, previously unrecognized biological and therapeutic complexity is emerging. Here, we synthesize lessons learned and discuss the steps required to extend the benefits of genome-driven oncology, including proposing strategies for improved drug design, mo...
#1Xuan Yang (Emory University)
#2Haian FuH-Index: 44
Last. Andrey A. Ivanov (Emory University)H-Index: 4
view all 3 authors...
The advances in cancer genomics, chemical biology, high-throughput screening technologies, and synthetic medicinal chemistry have tremendously expanded the biological space of cancer targets and chemical space of bioactive small molecules to interrogate oncogenic signaling. To explore and leverage these exponentially growing cancer-associated data, a great number of computational tools, databases, and algorithms have been developed. This review summarizes recent cancer-related web resources that...